Validation of MMS Test for Cancer Monitoring (MMS-TM)

June 20, 2018 updated by: MedInnovation GmbH

Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods

The purpose of this study is the validation of MMS test to detect active tumor growth in different cancer types before and after therapy, as well as in the course of therapy and for subsequent relapse control compared to standard methods (clinical examination, imaging, tumor markers). It should be consider whether the MMS test has comparable diagnostic accuracy, and thus can replace more expensive or invasive procedures in future.

Study Overview

Status

Terminated

Conditions

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Berlin, Germany, 13125
        • HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with primary diagnosis of cancer

Description

Inclusion Criteria:

  • Clinical diagnosis of colo-rectal cancer
  • Clinical diagnosis of stomach cancer
  • Suspected diagnosis of melanoma

Exclusion Criteria:

  • Colitis ulcerosa
  • Morbus Crohn
  • Cancer in time period two years before
  • Cancer therapy in time period two years before

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
MMS test
therapy monitoring of patients with colo-rectal or stomach disease or with melanoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
active tumor growth before and after cancer therapy
Time Frame: up to 36 month
up to 36 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

MedInnovation GmbH

Collaborators

Helios Klinikum Berlin-Buch

Investigators

  • Principal Investigator: Katja Waterstradt, PhD, MedInnovation GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2014

Primary Completion (ACTUAL)

June 20, 2018

Study Completion (ACTUAL)

June 20, 2018

Study Registration Dates

First Submitted

April 8, 2014

First Submitted That Met QC Criteria

April 10, 2014

First Posted (ESTIMATE)

April 15, 2014

Study Record Updates

Last Update Posted (ACTUAL)

June 21, 2018

Last Update Submitted That Met QC Criteria

June 20, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MMS-tm14

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Melanoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe